Cited by 392Pluripotent Stem Cells ResearchCRISPR and Genetic EngineeringDevelopmental Biology and Gene Regulation

Genome editing reveals a role for OCT4 in human embryogenesis

Open access
Fogarty, Norah M. E., McCarthy, Afshan, Snijders, Kirsten E., Powell, Benjamin E., Kubikova, Nada, Blakeley, Paul, Lea, Rebecca, Elder, Kay +10 more·2017·Nature

Abstract

Despite their fundamental biological and clinical importance, the molecular mechanisms that regulate the first cell fate decisions in the human embryo are not well understood. Here we use CRISPR-Cas9-mediated genome editing to investigate the function of the pluripotency transcription factor OCT4 during human embryogenesis. We identified an efficient OCT4-targeting guide RNA using an inducible human embryonic stem cell-based system and microinjection of mouse zygotes. Using these refined methods, we efficiently and specifically targeted the gene encoding OCT4 (POU5F1) in diploid human zygotes and found that blastocyst development was compromised. Transcriptomics analysis revealed that, in POU5F1-null cells, gene expression was downregulated not only for extra-embryonic trophectoderm genes, such as CDX2, but also for regulators of the pluripotent epiblast, including NANOG. By contrast, Pou5f1-null mouse embryos maintained the expression of orthologous genes, and blastocyst development was established, but maintenance was compromised. We conclude that CRISPR-Cas9-mediated genome editing is a powerful method for investigating gene function in the context of human development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature24033

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Germline editing has been used for years in animals, including mice, rats, monkeys and many others, and experiments show that it can be done in both nonviable or viable human embryos.

    “Germline editing has been used for years in animals, including mice, rats, monkeys and many others, and experiments show that it can be done in both nonviable or viable human embryos as well 110-113 .”

    From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [110]

    The Introduction (page unavailable) reports attempted CRISPR–Cas9 editing in abnormally fertilized tripronuclear and normally fertilized human zygotes, with variable success. The Results section reports editing in donated human IVF zygotes, and the paper discusses mouse embryo editing. Our copy does not substantiate the claim about rats, monkeys, or many other animals. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • A report of inaccurate CRISPR-Cas9-based genome editing in non-viable human embryos was not substantiated by later publications.

    “A report of inaccurate CRISPR-Cas9based genome editing in non-viable human embryos 110 was not substantiated by later publications, but the mechanism by which double-stranded DNA breaks are repaired in early human embryos remains under debate.”

    From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [110]

    The Results (Targeting POU5F1 in human preimplantation embryos; page unavailable) report efficient editing and no detectable off-target mutations above background in the embryos studied. That supports the idea that this later study did not reproduce inaccurate editing, but the paper does not establish that the earlier report involving non-viable embryos was unsubstantiated by later publications generally. (LLM, conf=0.79)

    Experimental — accuracy not yet measured
  • 57 of 137 successfully genotyped samples (42%) exhibited a homozygous wild-type genotype based on PCR amplification of a short genomic fragment.

    “Moreover, we identified that 57 of the 137 successfully genotyped samples (42%) exhibited a homozygous wild-type genotype based on PCR amplification of a short genomic fragment (17).”

    From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [17]

    The Methods section (Genomic DNA extraction and genotyping; page unavailable) describes PCR amplification of a 244-bp fragment and classifying samples with only the reference sequence as wild-type. Our copy does not report that 57 of 137 successfully genotyped samples (42%) had a homozygous wild-type genotype; searches for those numbers and percentage did not find the result. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In the authors' previous study, on-target genome editing was confirmed in all microinjected embryos and a stereotypic indel pattern was observed, with the majority of samples exhibiting a 2bp deletion.

    “We generated a number of single-cell amplified genomic DNA (gDNA) samples for genotyping and confirmed on-target genome editing in all microinjected embryos and a stereotypic insertion/deletion (indel) pattern of mutations with the majority of samples exhibiting a 2bp deletion (17).”

    From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [17]

    The Results section on targeting POU5F1 in human preimplantation embryos reports on-target indels in 71% (five of seven) of the microinjected embryos examined after cleavage arrest, not all of them. It identifies 2-bp and 3-bp deletions as the most frequent indels, but does not say that a majority of samples had a 2-bp deletion. Page numbers are unavailable in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Our previous findings in human embryos targeted post-fertilisation showed a stereotypic pattern to the type of indel mutations.

    “This corroborates our previous findings in human embryos targeted post-fertilisation, where we noted a stereotypic pattern to the type of indel mutations and speculated that this was likely due MMEJ (17).”

    From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [17]

    The Results section on human preimplantation embryos reports that 2-bp and 3-bp deletions were the most frequent indels after post-fertilisation editing, supporting a recurring mutation pattern. The paper explicitly calls the pattern “stereotypic” for mouse embryos, however, and the searched passages do not support the citing sentence’s additional attribution of an MMEJ explanation to this paper. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fogarty, N. M. E., McCarthy, A., Snijders, K. E., Powell, B. E., Kubikova, N., Blakeley, P., Lea, R., Elder, K., Wamaitha, S. E., Kim, D., Maciulyte, V., Kleinjung, J., Kim, J.-S., Wells, D., Vallier, L., Bertero, A., Turner, J. M. A., & Niakan, K. K.
Affiliations
  • The Francis Crick Institute (GB)
  • University of Cambridge (GB)
  • John Radcliffe Hospital (GB)
  • Bourn Hall Clinic (GB)
  • Seoul National University (KR)
  • Wellcome/MRC Cambridge Stem Cell Institute (GB)
Corresponding author
Niakan, Kathy K.
Venue
Nature
Published
2017-09-20
Volume
550
Issue
7674
Pages
67-73
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2759601393
Cited by
392
References
51
Citations by year
2026: 16 · 2025: 24 · 2024: 34 · 2023: 45 · 2022: 35 · 2021: 50 · 2020: 50 · 2019: 62 · 2018: 62 · 2017: 13
FWCI
20.88
Type
journal article
Language
en
Update notices
erratum (2017-10-04)
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Apollo (University of Cambridge) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
  • Apollo
Funders
  • Wellcome Trust (FC001193, FC001120)
  • Francis Crick Institute (10120, 10002, FC001193, 10193, FC001120)
  • Cancer Research UK (FC001120, FC001193)
  • National Institute for Health and Care Research
  • British Heart Foundation (FS/11/77/39327)
  • University of Oxford
  • Institute for Basic Science (IBSR021-D1, R021-D1)
  • Medical Research Council (PSAG028, FC001193, MC_PC_12009, FC001120)
  • Clarendon Fund
  • NIHR Cambridge Biomedical Research Centre
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
Keywords
Oct4, human embryonic development, blastocyst development, pluripotency transcription factors, trophectoderm, Nanog, epiblast, CRISPR/Cas9 genome editing, human zygotes, guide RNA design, placental development
MeSH terms
Human Embryonic Stem Cells, Nanog Homeobox Protein, Gene Editing, Animals, Blastocyst, Ectoderm, Embryo, Mammalian, Female, Germ Layers, Humans, Male, Substrate Specificity, Zygote, Gene Expression Regulation, Developmental, Cell Lineage, Embryonic Development, Octamer Transcription Factor-3, Mice, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review